Quest LaboratoriesNSE:QUESTLAB -1.56%44 ROC (Joel Greenblatt) % is 14.03% as of Mar. 2026, which is 71% below its 10-year median of 48.49. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 8 warning signs investors should review. Among 978 Drug Manufacturers companies, Quest Laboratories ranks worse than 62.99% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Quest Laboratories's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 14.03%.
The historical rank and industry rank for Quest Laboratories's ROC (Joel Greenblatt) % or its related term are showing as below:
NSE:QUESTLAB'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.51 Med: 48.49 Max: 67.83
Current: 3.51
During the past 6 years, Quest Laboratories's highest ROC (Joel Greenblatt) % was 67.83%. The lowest was 3.51%. And the median was 48.49%.
NSE:QUESTLAB's ROC (Joel Greenblatt) % is ranked worse than 62.99% of 978
companies
in the Drug Manufacturers industry
Industry Median: 11.32
vs NSE:QUESTLAB: 3.51
Quest Laboratories's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 9.00% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Quest Laboratories ROC (Joel Greenblatt) % Related Terms
Quest Laboratories ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 14.03% mean?
Quest Laboratories (NSE:QUESTLAB) has a ROC (Joel Greenblatt) % of 14.03% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Quest Laboratories and its competitors. This is 71% below median its historical median of 48.49. Over the past decade, Quest Laboratories' ROC (Joel Greenblatt) % has ranged from 3.51 to 67.83. According to the industry distribution chart, Quest Laboratories ranks #616 out of 978 companies in the Drug Manufacturers industry, placing it in the top 63%.
Is Quest Laboratories' ROC (Joel Greenblatt) % too high?
Quest Laboratories' current ROC (Joel Greenblatt) % of 14.03% is 71% below median its 10-year median of 48.49. Over the past 10 years, this metric has ranged from a low of 3.51 to a high of 67.83. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.32. Quest Laboratories' value of 14.03% is 23.9% above this industry median. Based on the distribution chart, Quest Laboratories ranks #616 out of 978 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' ROC (Joel Greenblatt) % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #616 out of 978 companies for ROC (Joel Greenblatt) %. This places Quest Laboratories in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.32. Quest Laboratories' value of 14.03% is 23.9% above this benchmark. Historically, Quest Laboratories' own ROC (Joel Greenblatt) % has ranged from 3.51 to 67.83 over the past decade. While the company's 10-year median is 48.49 vs. the industry median of 11.32, Quest Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.32, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current ROC (Joel Greenblatt) % of 14.03% is 23.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current ROC (Joel Greenblatt) % is 14.03%, which is 71% below median its own 10-year median of 48.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current ROC (Joel Greenblatt) % of 14.03%. The current ROC (Joel Greenblatt) % is 14.03%, which is 71% below median its 10-year median of 48.49 and 23.9% above the Drug Manufacturers industry median of 11.32. Quest Laboratories' overall GF Score™ is 44/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current ROC (Joel Greenblatt) % is 14.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 